Breakthrough infections in MPN-COVID vaccinated patients

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Barbui, Tiziano
• dc.contributor.author Andrade-Campos, Marcio
• dc.contributor.author Vannucchi, Alessandro Maria
• dc.date.accessioned 2023-02-24T07:44:41Z
• dc.date.available 2023-02-24T07:44:41Z
• dc.date.issued 2022
• dc.description.sponsorship The study was supported by a research grant by the COVID “3 × 1 project”, BREMBO S.p.A., Bergamo, Italy (T.B.) and by AIRC 5 × 1000 call “Metastatic disease: the key unmet need in oncology” to MYNERVA project, #21267 (MYeloid NEoplasms Research Venture AIRC). A detailed description of the MYNERVA project is available at https://progettomynerva.it (A.M.V., P.G.). The study was also supported by HARMONY PLUS, which is funded through the Innovative Medicines Initiative (IMI), Europe’s largest public–private initiative aiming to speed up the development of better and safer medicines for patients. The HARMONY Alliance has received funding from IMI 2 Joint Undertaking and is listed under grant agreement No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe.
• dc.format.mimetype application/pdf
• dc.identifier.citation Barbui T, Carobbio A, Ghirardi A, Iurlo A, De Stefano V, Sobas MA, et al. Breakthrough infections in MPN-COVID vaccinated patients. Blood Cancer J. 2022 Nov 15;12(11):154. DOI: 10.1038/s41408-022-00749-8
• dc.identifier.doi http://dx.doi.org/10.1038/s41408-022-00749-8
• dc.identifier.issn 2044-5385
• dc.identifier.uri http://hdl.handle.net/10230/55921
• dc.language.iso eng
• dc.publisher Nature Research
• dc.relation.ispartof Blood Cancer Journal. 2022 Nov 15;12(11):154
• dc.relation.projectID info:eu-repo/grantAgreement/EC/H2020/945406
• dc.rights Copyright © Barbui T, Carobbio A, Ghirardi A, Iurlo A, De Stefano V, Sobas MA, et al. 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by/4.0/
• dc.subject.other COVID-19 (Malaltia)
• dc.subject.other Infecció
• dc.subject.other Vacunes
• dc.title Breakthrough infections in MPN-COVID vaccinated patients
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion